Olov Ekwall

Olov Ekwall

Auto-generated profile, based on publicly available information

Olov Ekwall

Department of Pediatrics, Institute of Clinical Sciences, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
EOElizaveta Orlova
Elizaveta Orlova
LSLeila Sozaeva
Leila Sozaeva
RLRomain Lévy
Romain Lévy
AJAlyssa James
Alyssa James
Michail LionakisMichail Lionakis
Michail Lionakis
Patients with biallelic loss-of-function variants of AIRE suffer from autoimmune polyendocrine syndrome type-1 (APS-1) and produce a broad range of autoantibodies (auto-Abs), including circulating auto-Abs neutralizing most type I interferons (IFNs). These auto-Abs were recently reported to account for at least 10% of cases of life-threatening COVID-19 pneumonia in the general population. We report 22 APS-1 patients from 21 kindreds in seven countries, aged between 8 and 48 yr and infected with SARS-CoV-2 since February 2020. The 21 patients tested had auto-Abs neutralizing IFN-α subtypes and/or IFN-ω; one had anti–IFN-β and another anti–IFN-ε, but none had anti–IFN-κ. Strikingly, 19 patients (86%) were hospitalized for COVID-19 pneumonia, including 15 (68%) admitted to an intensive care unit, 11 (50%) who required mechanical ventilation, and four (18%) who died. Ambulatory disease in three patients (14%) was possibly accounted for by prior or early specific interventions. Preexisting auto-Abs neutralizing type I IFNs in APS-1 patients confer a very high risk of life-threatening COVID-19 pneumonia at any age.

6 March 2008 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
MAMohammad Alimohammadi
Mohammad Alimohammadi
PBPeyman Björklund
Peyman Björklund
ÅHÅsa Hallgren
Åsa Hallgren
NPNora Pöntynen
Nora Pöntynen
GSGabor Szinnai
Gabor Szinnai
OKOlle Kämpe
Olle Kämpe
Autoimmune polyendocrine syndrome type 1 (APS-1) is a multiorgan autoimmune disorder caused by mutations in AIRE, the autoimmune regulator gene. Though recent studies concerning AIRE deficiency have begun to elucidate the molecular pathogenesis of organ-specific autoimmunity in patients with APS-1, the autoantigen responsible for hypoparathyroidism, a hallmark of APS-1 and its most common autoimmune endocrinopathy, has not yet been identified. We performed immunoscreening of a human parathyroid complementary DNA library, using serum samples from patients with APS-1 and hypoparathyroidism, to identify patients with reactivity to the NACHT leucine-rich-repeat protein 5 (NALP5). Subsequently, serum samples from 87 patients with APS-1 and 293 controls, including patients with other autoimmune disorders, were used to determine the frequency and specificity of autoantibodies against NALP5. In addition, the expression of NALP5 was investigated in various tissues. NALP5-specific autoantibodies were detected in 49% of the patients with APS-1 and hypoparathyroidism but were absent in all patients with APS-1 but without hypoparathyroidism, in all patients with other autoimmune endocrine disorders, and in all healthy controls. NALP5 was predominantly expressed in the cytoplasm of parathyroid chief cells. NALP5 appears to be a tissue-specific autoantigen involved in hypoparathyroidism in patients with APS-1. Autoantibodies against NALP5 appear to be highly specific and may be diagnostic for this prominent component of APS-1.

13 October 2014 in Diabetes
Verified
Journal Article
Open access
TRTeresa Rodriguez-Calvo
Teresa Rodriguez-Calvo
OEOlov Ekwall
Olov Ekwall
NANatalie Amirian
Natalie Amirian
JZJose Zapardiel-Gonzalo
Jose Zapardiel-Gonzalo
MHMatthias G. von Herrath
Matthias G. von Herrath
Type 1 diabetes (T1D) results from a complex interplay between genetic susceptibility and environmental factors that have been implicated in the pathogenesis of disease both as triggers and potentiators of β-cell destruction. CD8 T cells are the main cell type found in human islets, and they have been shown in vitro to be capable of killing β-cells overexpressing MHC class I. In this study, we report that CD8 T cells infiltrate the exocrine pancreas of diabetic subjects in high numbers and not only endocrine areas. T1D subjects present significantly higher CD8 T cell density in the exocrine tissue without the presence of prominent insulitis. Even T1D donors without remaining insulin-containing islets and long disease duration show elevated levels of CD8 T cells in the exocrine compartment. In addition, higher numbers of CD4+ and CD11c+ cells were found in the exocrine tissue. Preliminary data in type 2 diabetic (T2D) subjects indicate that overall, there might be a spontaneous inflammatory infiltration of the exocrine tissue, common to both T1D and T2D subjects. Our study provides the first information on the precise tissue distribution of CD8 T cells in pancreata from T1D, T2D, autoantibody-positive, and healthy control subjects.

1 February 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ASAnnika Söderbergh
Annika Söderbergh
AMAnne Grethe Myhre
Anne Grethe Myhre
OEOlov Ekwall
Olov Ekwall
GGGennet Gebre-Medhin
Gennet Gebre-Medhin
HHHåkan Hedstrand
Håkan Hedstrand
TNThomas Nilsson
Thomas Nilsson
The prevalence of autoantibodies against nine intracellular enzyme autoantigens, namely 21-hydroxylase, side-chain cleavage enzyme (SCC), 17α-hydroxylase, glutamic acid decarboxylase 65, aromatic l-amino acid decarboxylase, tyrosine phosphatase-like protein IA-2, tryptophan hydroxylase (TPH), tyrosine hydroxylase, cytochrome P450 1A2, and against the extracellular calcium-sensing receptor, was assessed in 90 patients with autoimmune polyendocrine syndrome type I. A multivariate logistic regression analysis was performed for the presence of autoantibodies as independent predictors for different disease manifestations. Reactivities against 21-hydroxylase and SCC were associated with Addison’s disease with odds ratios (ORs) of 7.8 and 6.8, respectively. Hypogonadism was exclusively associated with autoantibodies against SCC with an OR of 12.5. Autoantibodies against tyrosine phosphatase-like protein IA-2 were associated with insulin-dependent diabetes mellitus with an OR of 14.9, but with low sensitivity. Reactivities against TPH and, surprisingly, glutamic acid decarboxylase 65, were associated with intestinal dysfunction, with ORs of 3.9 and 6.7, respectively. TPH reactivity was the best predictor for autoimmune hepatitis, with an OR of 27.0. Hypoparathyroidism was not associated with reactivity against any of the autoantigens tested. No reactivity against the calcium-sensing receptor was found. Analysis of autoantibodies in autoimmune polyendocrine syndrome type I patients is a useful tool for establishing autoimmune manifestations of the disease as well as providing diagnosis in patients with suspected disease.

1 July 1998 in The Lancet
Verified
Journal Article
Closed access
OEOlov Ekwall
Olov Ekwall
HHHåkan Hedstrand
Håkan Hedstrand
LGLars Grimelius
Lars Grimelius
JHJan Haavik
Jan Haavik
JPJaakko Perheentupa
Jaakko Perheentupa
FRFredrik Rorsman
Fredrik Rorsman

1 September 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HHHåkan Hedstrand
Håkan Hedstrand
OEOlov Ekwall
Olov Ekwall
MOMats J. Olsson
Mats J. Olsson
ELEva Landgren
Eva Landgren
EKElizabeth Helen Kemp
Elizabeth Helen Kemp
FRFredrik Rorsman
Fredrik Rorsman
Vitiligo is common in the hereditary disorder autoimmune polyendocrine syndrome type I (APS I). Patients with APS I are known to have high titer autoantibodies directed against various tissue-specific antigens. Using sera from APS I patients for immunoscreening of a cDNA library from human scalp, we identified the transcription factors SOX9 and SOX10 as novel autoantigens related to this syndrome. Immunoreactivity against SOX9 was found in 14 (15%) and against SOX10 in 20 (22%) of the 91 APS I sera studied. All patients reacting with SOX9 displayed reactivity against SOX10, suggesting shared epitopes. Among the 19 patients with vitiligo, 12 (63%) were positive for SOX10 (p < 0.0001). Furthermore, three of 93 sera from patients with vitiligo unrelated to APS I showed strong reactivity against SOX10, which may indicate a more general role of SOX10 as an autoantigen in vitiligo.